Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review
Abstract Background Cognitive impairment are among the core features of schizophrenia, experienced by up to 75% of patients. Available treatment options for schizophrenia including dopamine antagonists and traditional antipsychotic medications have not been shown to confer significant benefits on co...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-03-01
|
Series: | Neuropsychopharmacology Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/npr2.12382 |